Can remission be in juvenile idiopathic arthritis without the use of biological agents?

Objective: to evaluate the efficiency and safety of therapy with subcutaneous (SC) methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.Patients and methods. The paper presents the results of a prospective study of the efficacy and safety of MTX in...

ver descrição completa

Detalhes bibliográficos
Principais autores: S. I. Valieva, A. A. Glazyrina, N. N. Kuleshov, M. S. Dzis, S. Kh. Kurbanova, A. S. Sologub, E. A. Korobiyants, V. T. Yusupova
Formato: Artigo
Idioma:Russian
Publicado em: IMA-PRESS LLC 2019-09-01
coleção:Современная ревматология
Assuntos:
Acesso em linha:https://mrj.ima-press.net/mrj/article/view/932
_version_ 1826556854885416960
author S. I. Valieva
A. A. Glazyrina
N. N. Kuleshov
M. S. Dzis
S. Kh. Kurbanova
A. S. Sologub
E. A. Korobiyants
V. T. Yusupova
author_facet S. I. Valieva
A. A. Glazyrina
N. N. Kuleshov
M. S. Dzis
S. Kh. Kurbanova
A. S. Sologub
E. A. Korobiyants
V. T. Yusupova
author_sort S. I. Valieva
collection DOAJ
description Objective: to evaluate the efficiency and safety of therapy with subcutaneous (SC) methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.Patients and methods. The paper presents the results of a prospective study of the efficacy and safety of MTX in 247patients aged 1 to 17 years with articular variants of JIA, as well as the frequency of indications for prescribing biological agents for this category of patients. JIA occurred without systemic manifestations in all the patients, including 106 with oligoarticular articular JIA, 94 with rheumatoid factor (RF)-negative polyarticular JIA, 15 with RF-positive polyarticular JIA, 20 with enthesitis-related JIA, and 12 with psoriatic arthritis. JIA was diagnosed according to the ILAR criteria. After verification of the diagnosis, all the patients were prescribed SC injections of MTX at a dose of 15 mg/m2/week.Results and discussion. After 3 months of MTX therapy, 50 and 70% improvements according to the ACR pediatric criteria were registered in 65 and 53% of the patients, respectively. After 6, 9, and 12 months of therapy, the stage of inactive disease or remission was observed in 44.5, 85, and 100% of the patients, respectively.Conclusion. Parenteral MTX administration contributes to the achievement of disease remission and the restoration of joint functions in patients with JIA without extra-articular manifestations. Along with its high therapeutic efficacy, MTX had a good tolerability and a favorable safety profile.
first_indexed 2024-04-10T02:06:36Z
format Article
id doaj.art-a303eba5853c4bc4bb94185647ce17d1
institution Directory Open Access Journal
issn 1996-7012
2310-158X
language Russian
last_indexed 2025-03-14T08:19:19Z
publishDate 2019-09-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj.art-a303eba5853c4bc4bb94185647ce17d12025-03-02T13:11:02ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2019-09-01133455010.14412/1996-7012-2019-3-45-502188Can remission be in juvenile idiopathic arthritis without the use of biological agents?S. I. Valieva0A. A. Glazyrina1N. N. Kuleshov2M. S. Dzis3S. Kh. Kurbanova4A. S. Sologub5E. A. Korobiyants6V. T. Yusupova7Morozov City Children's Clinical Hospital, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Heath of RussiaMorozov City Children's Clinical Hospital, Moscow Healthcare DepartmentMorozov City Children's Clinical Hospital, Moscow Healthcare DepartmentMorozov City Children's Clinical Hospital, Moscow Healthcare DepartmentMorozov City Children's Clinical Hospital, Moscow Healthcare DepartmentMorozov City Children's Clinical Hospital, Moscow Healthcare DepartmentMorozov City Children's Clinical Hospital, Moscow Healthcare DepartmentMorozov City Children's Clinical Hospital, Moscow Healthcare DepartmentObjective: to evaluate the efficiency and safety of therapy with subcutaneous (SC) methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.Patients and methods. The paper presents the results of a prospective study of the efficacy and safety of MTX in 247patients aged 1 to 17 years with articular variants of JIA, as well as the frequency of indications for prescribing biological agents for this category of patients. JIA occurred without systemic manifestations in all the patients, including 106 with oligoarticular articular JIA, 94 with rheumatoid factor (RF)-negative polyarticular JIA, 15 with RF-positive polyarticular JIA, 20 with enthesitis-related JIA, and 12 with psoriatic arthritis. JIA was diagnosed according to the ILAR criteria. After verification of the diagnosis, all the patients were prescribed SC injections of MTX at a dose of 15 mg/m2/week.Results and discussion. After 3 months of MTX therapy, 50 and 70% improvements according to the ACR pediatric criteria were registered in 65 and 53% of the patients, respectively. After 6, 9, and 12 months of therapy, the stage of inactive disease or remission was observed in 44.5, 85, and 100% of the patients, respectively.Conclusion. Parenteral MTX administration contributes to the achievement of disease remission and the restoration of joint functions in patients with JIA without extra-articular manifestations. Along with its high therapeutic efficacy, MTX had a good tolerability and a favorable safety profile.https://mrj.ima-press.net/mrj/article/view/932juvenile idiopathic arthritismethotrexateremission
spellingShingle S. I. Valieva
A. A. Glazyrina
N. N. Kuleshov
M. S. Dzis
S. Kh. Kurbanova
A. S. Sologub
E. A. Korobiyants
V. T. Yusupova
Can remission be in juvenile idiopathic arthritis without the use of biological agents?
Современная ревматология
juvenile idiopathic arthritis
methotrexate
remission
title Can remission be in juvenile idiopathic arthritis without the use of biological agents?
title_full Can remission be in juvenile idiopathic arthritis without the use of biological agents?
title_fullStr Can remission be in juvenile idiopathic arthritis without the use of biological agents?
title_full_unstemmed Can remission be in juvenile idiopathic arthritis without the use of biological agents?
title_short Can remission be in juvenile idiopathic arthritis without the use of biological agents?
title_sort can remission be in juvenile idiopathic arthritis without the use of biological agents
topic juvenile idiopathic arthritis
methotrexate
remission
url https://mrj.ima-press.net/mrj/article/view/932
work_keys_str_mv AT sivalieva canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents
AT aaglazyrina canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents
AT nnkuleshov canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents
AT msdzis canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents
AT skhkurbanova canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents
AT assologub canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents
AT eakorobiyants canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents
AT vtyusupova canremissionbeinjuvenileidiopathicarthritiswithouttheuseofbiologicalagents